Leading Rhode Island researchers reacted with disappointment Friday to word that Cambridge-based pharmaceutical firm Biogen and its Japanese partner Eisai are stopping Phase 3 clinical trials of Aducanumab, a drug that had raised hopes of slowing the advance of Alzheimer’s disease.